Background & Aims: We evaluated the efficacy and safety of infliximab for inducing and maintaining benefit in children with moderately to severely active ulcerative colitis (UC). Methods: Patients (6-17 years old) who had active UC (Mayo scores of 6-12; endoscopic subscores ≥2) and had not responded to or tolerated conventional treatment were given 5 mg/kg infliximab at weeks 0, 2, and 6. The primary end point was response at week 8 (decreases in Mayo scores ≥30% and ≥3 points and decreases in rectal bleeding subscores of ≥1 or an absolute subscore of ≤1). At week 8, only responders were randomly assigned to groups given infliximab every 8 or 12 weeks (q8w or q12w) and followed through week 54. Maintenance end points included pediatric UC activity index scores <10 points, defined as remission. Results: At week 8, infliximab induced a response in 73.3% of patients (44 of 60) (95% confidence interval, 62.1%-84.5%; a positive result was defined by 95% confidence interval lower limit >40%). Among responders, twice as many were in remission at week 54 after q8w (8 of 21, 38.1%) than q12w (4 of 22, 18.2%; P = .146) therapy. Assuming the q8w remission rate for responders, the overall remission rate at week 54 would be 28.6%. Serious adverse events and infusion reactions occurred in similar proportions in the q8w and q12w groups. No deaths, malignancies, opportunistic infections, tuberculosis, or delayed hypersensitivity reactions were reported. Conclusions: Infliximab was safe and effective, inducing a response at week 8 in 73.3% of pediatric patients with moderate to severely active UC who did not respond to conventional therapy. The overall remission rate at week 54 for all enrolled patients was 28.6%, assuming the more effective q8w remission rate.

, , ,,
Clinical Gastroenterology and Hepatology
Department of Pediatrics

Hyams, J.S, Damaraju, L.V, Blank, M, Johanns, J, Guzzo, C, Winter, H, … Griffiths, A.M. (2012). Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 10(4), 391–399. doi:10.1016/j.cgh.2011.11.026